Study of CD38 and CD56 in Chronic Myeloid Leukemia
August 4, 2026 updated by: Mennatallah Mostafa Zaki, Sohag University
Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Menna Mostafa Zaki
- Phone Number: 01152386116
- Email: mennazaki133@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
patients in sohag city
Description
Inclusion Criteria:
- patients with chronic myeloid leukemia
Exclusion Criteria:
- other hematological diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
healthy group
|
|
|
chronic myeloid leukemia group
|
prescence of high percentage of cd38 and cd 56
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
an increased change in cd 38 and cd 56 in chronic leukemic patients
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
July 1, 2027
Study Registration Dates
First Submitted
July 25, 2026
First Submitted That Met QC Criteria
July 29, 2026
First Posted (Actual)
July 31, 2026
Study Record Updates
Last Update Posted (Actual)
August 5, 2026
Last Update Submitted That Met QC Criteria
August 4, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Chronic Disease
- Disease Attributes
- Neoplasms by Histologic Type
- Hematologic Diseases
- Leukemia, Myeloid
- Bone Marrow Diseases
- Leukemia
- Myeloproliferative Disorders
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Other Study ID Numbers
- Soh-Med-26-6-9MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.